- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jeanne Tie
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovering epigenetic silencing mechanisms in female stem cells
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Epigenetics – genome wide multiplexed single-cell CUT&Tag assay development
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Mechanisms of Wnt secretion and transport
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Single-cell ATAC CRISPR screening – Illuminate chromatin accessibility changes in genome wide CRISPR screens
- Spatial single-cell CRISPR screening – All in one screen: Where? Who? What?
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structural basing for Wnt acylation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- Validation and application of serological markers of previous exposure to malaria
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- Donors
- WEHI.TV
Study shows benefit of universal genetic testing after breast cancer diagnosis
4 May 2023
A study of women recently diagnosed with breast cancer has found many have identifiable and well understood gene abnormalities, and yet they are excluded from subsidised genetic testing that can guide their treatment.
At a glance
- Current genetic testing guidelines for women with breast cancer only extend to patients where the risk of carrying a faulty gene is 10% or greater.
- Researchers expanded genetic testing to all women in a cohort of patients with newly diagnosed breast cancer and found 58% of patients with a faulty gene had a risk factor of less than 10%.
- The study found that offering universal genetic testing has the potential to improve outcomes by identifying hereditary mutations in patients that leads to altered management and testing of family members.
researcher in the study
According to Australian guidelines, women with newly diagnosed breast cancer should be offered genetic testing when they meet certain strict criteria - such as being diagnosed at a very young age or if many family members have had breast cancer - amounting to a 10% or more risk of having a rare, hereditary gene mutation.
The Melbourne-based study provided genetic testing to 474 women with newly diagnosed breast cancers irrespective of their risk of having a gene abnormality, such as BRCA1 or BRCA2 mutations.
Faulty cancer-causing genes were identified in 31 of the women and more than half (18) of these patients would not have been eligible for genetic testing under the current guidelines.
The study is a collaboration between the Parkville Breast Service (Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Royal Women’s Hospital), the Parkville Familial Cancer Centre and WEHI, and results are published today in the Medical Journal of Australia.
Universal screening provides missing vital link for many
Peter Mac’s Professor Ian Campbell said the study showed that current Medicare-funded testing guidelines mean many patients miss out on vital information that could change the course of their treatment.
“Our study expanded this genetic testing to all women with newly diagnosed breast cancer and found 58% of patients identified as having a faulty gene had a risk factor of less than 10%, meaning these patients would not have been picked up under current screening guidelines,” said Prof Campbell, who is head of the Cancer Genetics Laboratory at Peter Mac.
“This demonstrates that more than half of breast cancer patients are missing out on their treatment being properly managed based on additional genetic information currently unavailable to them and their treating team.”
“The adoption of universal genetic testing for women with newly diagnosed breast cancer has the potential to improve outcomes by identifying hereditary mutations in patients and their families, leading to better treatment options and outcomes,” he said.
Genetic risk factors impact treatment decisions
Approximately 5% of breast cancers occur in people who have inherited a gene abnormality from a parent.
WEHI’s Professor Geoff Lindeman said identifying these cases was vital to providing the best medical advice and intervention to patients and their wider families, and it often impacted surgery decisions.
“For example, a patient with a BRCA1 or BRCA2 gene mutation may choose to have a double mastectomy, rather than radiation therapy,” said Prof Lindeman, who is also a medical oncologist at Peter Mac and the Royal Melbourne Hospital.
“Similarly, a patient with a high risk of developing ovarian cancer might elect to have their ovaries removed as a preventative measure.”
“When a faulty gene is found, it also means family members can be tested and referred to a familial cancer clinic to manage their risk factor for developing breast or ovarian cancer.”
Professor Bruce Mann, Head of the Parkville Breast Service, said for most women in the study identified as having a gene abnormality, their recommended treatment changed as a result.
“With this additional information, the multidisciplinary team modified treatment recommendations for 77% of the women with hereditary mutations, including those not currently eligible for Medicare-funded testing,” Prof Mann said.
“We were able to incorporate this genetic testing into our existing multidisciplinary model of care, expediting treatment for patients.”
“Having their doctors initiate genetic counselling and testing streamlined the process and improved access to testing.”
No regrets about being tested
Associate Professor Lesley Stafford, a clinical psychologist at the Royal Melbourne Hospital and the Parkville Familial Cancer Centre, said the research also found strong acceptance of genetic testing.
“Of the women who participated in our study, 87% agreed or strongly agreed that all women with breast cancer should be offered genetic testing,” she said.
“There was no decision regret among the participants in our study about having the genetic testing.”
The research was supported by funding from the National Breast Cancer Foundation and the National Health and Medical Research Council.
The study, ‘Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care’, is published in the Medical Journal of Australia (DOI: https://doi.org/10.5694/mja2.51906).
WEHI authors: Kirsten Hogg, Luxi Lal and Geoffrey Lindeman.
Media enquiries
M: +61 475 751 811
E: communications@wehi.edu.au
Super Content:
Professor Geoff Lindeman answers frequently asked questions about the BRCA1 gene
Want to be informed of our most exciting discoveries? Subscribe to our quarterly newsletter, Illuminate.